References
- Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6. doi:10.1038/s41572-020-00240-3.
- Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589–3.
- Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;149:1226–39 e4.
- Guegan JP, Lapouge M, Voisin L, Saba-El-Leil MK, Tanguay P-L, Lévesque K, Brégeon J, Mes-Masson A-M, Lamarre D, Haibe-Kains B, et al. Signaling by the tyrosine kinase Yes promotes liver cancer development. Sci Signal. 2022;15:eabj4743. doi:10.1126/scisignal.abj4743.
- Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene. 2004;23(48):7906–7909. doi:10.1038/sj.onc.1208160.
- Kim LC, Song L, Haura EB. Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 2009;6:587–595. doi:10.1038/nrclinonc.2009.129.
- Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337–358. doi:10.1023/A:1023772912750.
- Hansen CG, Moroishi T, Guan KL. YAP and TAZ: a nexus for Hippo signaling and beyond. Trends Cell Biol. 2015;25:499–513.
- Zheng Y, Pan D. The Hippo signaling pathway in development and disease. Dev Cell. 2019;50:264–282. doi:10.1016/j.devcel.2019.06.003.
- Li P, Silvis MR, Honaker Y, Lien WH, Arron ST, Vasioukhin V. alphaE-Catenin inhibits a Src-YAP1 oncogenic module that couples tyrosine kinases and the effector of Hippo signaling pathway. Genes Dev. 2016;30:798–811. doi:10.1101/gad.274951.115.